Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.18%
#3 CoW Protocol CoW Protocol +44.40%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.78%
#6 Walrus Walrus +24.24%
#7 Codatta Codatta +19.91%
#8 Enso Enso +18.69%
#9 Collector Crypt Collector Crypt +14.14%
#10 The Black Bull The Black Bull +13.35%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Classifica tra le azioni #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Prezzo delle azioni
$0.117
Ultima sincronizzazione: 2025-04-04
Capitalizzazione di mercato
$2.45M
Variazione (1 giorno)
-13.59%
Variazione (1 anno)
0.00%
Paese
US
Scambia Carmell Therapeutics Corporation (CTCX)

Categoria

Healthcare
Ricavi di Carmell Therapeutics Corporation (CTCX)
Ricavi nel Jun 2026 TTM: $1.69M
Secondo gli ultimi rapporti finanziari di Carmell Therapeutics Corporation, i ricavi attuali dell'azienda (TTM) sono pari a $1.69M. Nel 2023, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2022, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Carmell Therapeutics Corporation da 2021 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $1.69M 3,251.88%
2024 $50.32K 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 748,405.43%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 356,907.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 599,377.10%
BE